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TGFb1 Inhibits the Formation of Benign
Skin Tumors, but Enhances Progression to Invasive
Spindle Carcinomas in Transgenic Mice
Wei Cui,*‡ Deborah J. Fowlis,*§ Sheila Bryson,† have been reported in some human carcinomas (Gar-
Elizabeth Duffie,* Hazel Ireland,* Allan Balmain,† rigue-Antar etal., 1995; Markowitz et al., 1995).However,
and Rosemary J. Akhurst* many mouse and human tumors have intact TGFb re-
*Department of Medical Genetics ceptors and retain growth sensitivity to TGFb1 (Wake-
†Cancer Research Campaign Beatson Laboratories field et al., 1987; W. C., unpublished data), loss of the
Department of Medical Oncology negative growth response generally being a late event
Glasgow University in multistage carcinogenesis (Haddow et al., 1991) prob-
Glasgow, G12 8QQ ably owing to a defect in downstream signaling (W. C.,
United Kingdom unpublished data).
At early stages of carcinogenesis, TGFb1 has been
reported to act as a tumor promoter (Furstenberger et
Summary al., 1989; Sieweke et al., 1990), an endogenous regulator
of epidermal homeostasis (Akhurst et al., 1988; Cui et
TGFb1 has been implicated in cell cycle control and al., 1995), or a tumor suppressor (Pierce et al., 1995). At
carcinogenesis. To address the exact function of later stages, this growth factor has been reported either
TGFb1 in skin carcinogenesis in vivo, mice with TGFb1 to suppress (Arteaga et al., 1990; Wu et al., 1992, 1993;
expression targeted to keratinocytes were subjected Glick et al., 1993, 1994; Cui et al., 1994; Sun et al., 1994)
to long-term chemical carcinogenesis treatment. or to stimulate (Welch et al., 1990; Torre-Amione et al.,
TGFb1 showed biphasic action during multistage skin 1990; Arrick et al., 1992; Gorsch et al., 1992; Steiner and
carcinogenesis, acting early as a tumor suppressor Barrack, 1992; Arteaga et al., 1993a, 1993b; Arteaga et
but later enhancing the malignant phenotype. The al., 1990; Chang et al., 1993) malignant progression. The
transgenics were more resistant to induction of benign stimulation of malignant progression could be attributed
skin tumors than controls, but the malignant conver- to the actions of TGFb1 on cell–matrix interactions that
sionrate was vastly increased. There was also ahigher modulate cellular plasticity or cell survival (Heino and
incidence of spindle cell carcinomas, which expressed
Massague, 1989; Arrick et al., 1992; Chakrabarty, 1992;
high levels of endogenous TGFb3, suggesting that
Samuel et al., 1992; Chang et al., 1993; Wang et al.,
TGFb1 elicits an epithelial–mesenchymal transition in
1995), in enhancing angiogenesis (Roberts et al., 1986)vivo and that TGFb3 might be involved in maintenance
or as an immunosuppressive factor (Torre-Amione etof the spindle cell phenotype. The action of TGFb1 in
al., 1990; Arteaga et al., 1993b). In particular, epithelialenhancing malignant progression may mimic its pro-
cells cultured in vitro, or injected subcutaneously intoposed function in modulating epithelial cell plasticity
nude mice to produce tumors, have been shown to un-during embryonic development.
dergo an epithelial–mesenchymal transition to a spindle
cell type under the influence of TGFb1 (Miettinen et al.,Introduction
1994; Caulin et al., 1995; G. Portella et al., unpublished
data).The secreted factor transforming growth factor b1
We have attempted to resolve the multiple, and some-(TGFb1) has been proposed to play an important role
times contradictory, roles of TGFb1 in skin carcinogene-in epithelial carcinogenesis, since it is known to be both
sis in vivo using transgenic mice with keratinocyte-a potent negative epithelial cell growth regulator and a
targeted expression of TGFb1. Previously, long-termmodulator of cellular phenotype (Roberts and Sporn,
chemical carcinogenesis studies utilizing TGFb1 keratin1990; Alexandrow and Moses, 1995; Cui and Akhurst,
promoter transgenic mice or TGFb1null animals have not1996). Furthermore, TGFb1 is induced in mouse epider-
been possible because of the early death of thesemis in response to the tumor promoter 12-O-tetradeca-
noylphorbol-13-acetate (TPA) (Akhurst et al., 1988; Krieg transgenic and knockout lines (Sellheyer et al., 1993;
et al., 1991; Fowlis et al., 1992), and its expression is Glick et al., 1994). We have recently generated and char-
often elevated in tumor cells in vivo (Derynck et al., 1987; acterized a number of keratin promoter TGFb1 trans-
Dickson et al., 1987; Gomella et al., 1989). However, genic lines, which express recombinant TGFb1 and are
much controversy exists as to its exact contribution, if viable in the homozygous state (Cui et al., 1995; Fowlis
any, to the outgrowth and phenotype of tumors in vivo. et al., 1996). These have allowed us to examine the
Loss of the growth response to TGFb1 occurs in some influence of TGFb1 on the induction and progression of
human and mouse tumors (Terzaghi-Howe, 1989; Had- skin tumors in vivo.
dow et al., 1991; Manning et al., 1991; Missero et al., The mouse skin model of multistage carcinogenesis
1991) and might contribute to tumor outgrowth. Indeed, is ideally suited to investigations of this kind, since it has
genetic mutations in the TGFb type II receptor, TbRII, been well characterized with respect to both phenotypic
and genetic changes (Kemp et al., 1994; Yuspa et al.,
‡Present address: Division of Molecular Biology, Roslin Institute, 1995). Tumor initiation involves mutation of codon 61
Roslin, Midlothian, United Kingdom.
of the H-ras gene, brought about by a single topical§Present address: Biotechnical and Biological Science Research
application of the mutagen, dimethylbenzanthraceneCouncil Centre for Genome Research, Edinburgh University, Edin-
burgh, United Kingdom. (DMBA). Repeated biweekly application of the tumor
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Table 1. Summary of Transgenic Lines
Transgenic Transgene Copy
Line Transgene Number Expression
D K6–mTGFb1 2–3 TPA inducible
F K6–mTGFb1 2–3 TPA inducible
H K10–sTGFb1act 2–3 Constitutive
M2 K6–sTGFb1act z8 TPA inducible
M5 K6–sTGFb1act z30 TPA inducible
promoter, TPA, leads to the outgrowth of highly differen-
tiated benign papillomas by around 15 weeks postinitia-
tion. After a further 10–15 weeks, a small subset of papil-
lomas eventually progress to malignant squamous
carcinoma. Finally, a small portion of these carcinomas
undergo an epithelial to mesenchymal transformation
to the most malignant tumor type, the spindle cell carci-
noma (Klein-Szanto et al., 1989; Buchmann et al., 1991).
The spindle cell, the most invasive, motile carcinoma
cell type, has altered expression of keratinocyte-specific
markers, such as cytokeratins, and loss of E-cadherin
expression and is characterized by expression of fibro-
blastoid cell markers, such as vimentin (Stoler et al.,
1993; Caulin et al., 1995).
Here we show that TGFb1 appears to have different
functions at early and late stages of tumorigenesis. It
acts as a suppressor of benign tumor outgrowth, but
later accelerates malignant conversion and the squa-
mous to spindle cell transformation.
Results
TGFb1 Suppresses Benign Tumor
Outgrowth In Vivo Figure 1. TGFb1 Suppresses Outgrowth of Benign Skin Papillomas
Five homozygous TGFb1 transgenic mouse lines were Three independent chemical carcinogenesis experiments were per-
utilized for chemical carcinogenesis studies (Table 1). formed utilizing 10 control, 13 F line, and 7 H line mice (A); 12 control,
Line H is transgenic for a construct driving constitutive 23 H line, 21 D line, and 11 M2 line mice (B); and 17 control and 21
M5 line mice (C). Within each experiment, DMBA treatment wasexpression of activated simian TGFb1 (sTGFb1act) in su-
performed on each animal at the same time, and each animal wasprabasal keratinocytes of the skin, utilizing a bovine KVI
subsequently treated identically. Tumor numbers were counted(corresponding to human keratin 10 [K10]) gene pro-
each week, and the cumulative average per mouse was plotted
moter (Cui et al., 1995). The M2 and M5 lines drive ex- versus weeks post-DMBA treatment. By 26 weeks, when the tumor
pression of sTGFb1act in suprabasal keratinocytes, but numbers were reaching plateau, the average tumor number per
utilize an inducible keratin gene promoter, KIV* (corre- mouse in the transgenics was reduced by up to 6-fold compared
with controls (P values all < 0.05 using a Student’s one-tailed t test).sponding to human K6), which is only expressed in the
However, it should be emphasized that this is a minimal estimatehyperplastic state, for example following topical appli-
of tumor suppression since, for reasons of humanity, several controlcation of TPA or in hyperplastic keratinocytes of papillo-
mice with very high benign tumor loads were prematurely removed
mas and carcinomas (Fowlis et al., 1996). The D and F from the study.
line mice are transgenic for the inducible K6 promoter
driving expression of native, latent murine (m)TGFb1
(Fowlis et al., 1996). All five lines gave qualitatively simi- to malignant carcinoma. The benign tumor latency, of
8–9 weeks, was the same in both control and transgeniclar results in chemical carcinogenesis experiments, re-
gardless of the gene promoter used or the nature of the groups (Figure 1). However, there was a consistent and
significant reduction in the benign tumor number perencoded TGFb1 protein, although the M2 line showed
the most dramatic effects. mouse in the transgenic compared with the control
group throughout 26 weeks of observation (Figure 1).Three independent chemical carcinogenesis experi-
ments were performed utilizing 135 mice from D, F, H, Suppression of benign tumor outgrowth was apparent
as early as 9 weeks post-DMBA in the first experimentM2, and M5 lines and controls (Figure 1). Animals were
initiated by a single treatment with DMBA, followed by and clear by 13 weeks post-DMBA in all three experi-
ments. The effect was greatest in the M2 and D lines,tumor promotion by twice weekly application of TPA for
20 weeks. This treatment normally results in the out- in which the benign tumor number per mouse at 26
weeks post-DMBA was reduced 6-fold compared withgrowth of benign tumors, a minority of which progress
TGFb1 in Multistage Carcinogenesis
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Table 2. TGFb1 Increases Malignant Progression Rate and Enhances the Spindle Cell Conversion
Squamous Squamous
Mouse Number of First Carcinoma Number of Carcinomas per Carcinoma Carcinoma Spindle Cell
Line Mice Appearance (weeks) Number of Papillomasa Grade I–II Grade III–IV Carcinoma
Control 39 .26 8 of 532 3 4 1
D 21 18 11 of 77 6 4 1
F 13 23 4 of 105 0 4 0
H 30 22 8 of 235 0 6 2
M2 11 20 7 of 40 4 1 2
M5 21 15 6 of 159 0 2 4
Following chemical carcinogenesis treatment, the appearance of the first carcinoma was noted for each mouse line. At the termination of the
experiment (44 weeks post-DMBA), all carcinomas were enumerated, and histological analysis was performed. Carcinomas were scored as
well-differentiated squamous carcinoma (grade I–II), poorly differentiated squamous carcinoma (grade III–IV), or aggressive spindle cell
carcinomas. Note the reduced latency before carcinoma appearance and the prevalence of spindle cell carcinomas in the transgenic mice.
Also note that the data in Table 2 were collected at the termination of the experiment (44 weeks post-DMBA), in contrast with the data in
Figures 1 and 2, which derived from observations at 26 weeks post-DMBA.
a Cumulative carcinoma total at 44 weeks per cumulative papilloma total at 26 weeks.
the control group (Figure 1). These data unequivocally
demonstrate that, at early stages of chemical carcino-
genesis, keratinocyte-derived TGFb1 is not a tumor pro-
moter, but suppresses benign tumor outgrowth, proba-
bly via its growth-inhibitory or differentiation-inducing
effects on the initiated cell.
TGFb1 Enhances Malignant Conversion
Rate In Vivo
Despite the relative paucity of benign tumors on the
transgenic mice, those tumors that did develop had a
very high malignant conversion frequency, manifested
as an earlier appearance of carcinoma (Table 2) and
an absolute increase in the number of carcinomas per
mouse relative to the control group (Figure 2B). At 26
weeks post-DMBA, none of the 532 control papillomas
had progressed to carcinoma, contrasting with a malig-
nant conversion frequency of 12.5% (5 of 40) for the M2
line and 7.8% (5 of 77) for the D line mice (Figure 2A).
In conclusion, although keratinocyte-derived TGFb1 in-
hibited papilloma outgrowth, the papillomas that devel-
oped were at high risk for malignant conversion, re-
sulting in an overall increase in malignant tumor number
despite a reduction in total (benign plus malignant) tu-
mor number.
TGFb1 Stimulates the Squamous to Spindle
Cell Transformation In Vivo
In addition to the increased malignant conversion fre-
quency in transgenics compared with controls, there
was a notable increase in the incidence of highly malig-
nant spindle cell carcinomas in the transgenic mice.
Indeed, at the termination of the experiment, after 44
weeks, over one third of carcinomas (8 of 21) from
transgenicmice expressing sTGFb1act were highly malig- Figure 2. TGFb1 Enhances the Malignant Conversion Frequency of
nant spindle carcinomas, compared with only one eighth Benign Papillomas
(1 of 8) for control carcinomas (Table 2). This is in spite Mice were subjected to chemical carcinogenesis treatment, and 26
weeks post-DMBA the total papilloma and carcinoma numbers wereof the fact that the average papilloma number was sub-
recorded. The data from three independent experiments (Figure 1)stantially higher in controls than in transgenic mice (Fig-
were pooled and presented as (A) the malignant conversion fre-ure 1).
quency (number of carcinomas per number of papillomas, shown
above each bar) and (B) total carcinomas per mouse (number ofRecombinant TGFb1 Is Expressed in Papillomas carcinomas per number of mice, shown above each bar). Although
and Squamous Carcinomas the average papilloma number per mouse was reduced for the
We have previously shown that the K10–sTGFbact transgenics (Figure 1), the average carcinoma number per mouse
was increased (B).transgene is constitutively expressed, at low levels, in
Cell
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Figure 3. Expression of Recombinant and
Endogenous TGFbs in Papillomas and Carci-
nomas
Paraffin sections (5 mm) of tumors from M2
line mice were subjected to in situ hybridiza-
tion using a 35S-labeled transgene-specific
probe (A–F) (Cui et al., 1995) or a 35S-labeled
TGFb3-specific probe (G–I). Bright-field (left)
and dark-field (right) images are shown.
(A and B) Transgene expression in the imme-
diate suprabasal keratinocytes of a pap-
illoma.
(C and D) A squamous carcinoma with re-
gions that are well (w) and poorly differenti-
ated (p). Transgene expression is limited to
the immediate suprabasal layer of the well-
differentiated region and to isolated differen-
tiated keratinocytes of the poorly differenti-
ated region.
(E and F) A spindle cell carcinoma, which
does not express the transgene.
(G and H) A squamous carcinoma with re-
gions that are well differentiated (w), where
TGFb3 expression is restricted to basal kera-
tinocytes, or poorly differentiated (p), charac-
terized by high levels of TGFb3 expression.
(I and J) An overt spindle cell carcinoma
showing a characteristic high level of TGFb3
expression.
Abbreviations are as follows: b, basal kera-
tinocyte; ep, epidermis; h, hair follicle; p,
poorly differentiated region of squamous tu-
mor; s, suprabasal keratinocyte; sp, spindle
carcinoma; w, well-differentiated region of
squamous tumor. All frames are of the same
magnification, and the scale bar represents
200 mm.
suprabasal keratinocytes (Cui et al., 1995) and that the Nelson and Slaga, 1982; Toftgard et al., 1985; Roop et
al., 1988). Expression of the K10 transgene (H line) wasK6 transgenes are expressed in hyperplastic suprabasal
keratinocytes after TPA treatment (Fowlis et al., 1996). considerably reduced in papillomas and carcinomas
compared with normal skin (data not shown). In contrast,The increase in malignant conversion frequency seen in
the transgenic animals could be attributed to an early K6-derived transcripts were expressed at very high lev-
els in suprabasal keratinocytes of papillomas and well-selection for a high risk papilloma subtype during the
tumor promotion phase (Hennings et al., 1985) and/or to differentiated carcinomas and in isolated suprabasal
cells of poorly differentiated squamous carcinomas (Fig-persistent overexpression of recombinant TGFb1 within
the papillomas, directly modulating the tumor pheno- ures 3A–3D). The spindle cell carcinomas no longer ex-
pressed either transgene (Figures 3E–3F).type. It was therefore important to determine whether
or not recombinant TGFb1 was expressed in the benign Determination of recombinant TGFb1 protein expres-
sion was more problematic, as previously reported bypapillomas. In situ hybridization analysis with a trans-
gene-specific probe showed that the transgenes be- ourselves and others (Sellheyer et al., 1993; Cui et al.,
1995). Immunohistochemistry utilizing two anti-TGFb1haved in a manner expected from the endogenous ex-
pression profiles of K10 and K6 (Winter et al., 1980; antibodies (Flanders et al., 1989) showed no quantitative
TGFb1 in Multistage Carcinogenesis
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Figure 4. Expression of TGFb1 Protein in
Transgenic Papillomas
(A) shows a control papilloma stained with
anti-pre-266-278-1 TGFb1 antibody.
(B) shows a D line papilloma stainedwith anti-
pre-266-278-1 TGFb1 antibody. Scale bar
represents 250 mm.
difference in TGFb1 protein expression between carcinomas (including transgenics and controls) to in
situ hybridization utilizing isoform-specific probes fortransgenic and control tumors. However, a third anti-
body (anti-pre-266-278-1) against the latency-associ- TGFb1, TGFb2, and TGFb3 (Fitzpatrick et al., 1990). Ad-
ditionally, 5 spindle cell carcinomas were subjected toated peptide (Wakefield et al., 1990), though variable,
was more intense in transgenic papillomas compared immunohistochemical analysis with the anti-pre-266-
278-1 antibody. The most striking observation was thatwith controls (Figure 4), supporting the hypothesis that
continued expression of the transgene, at least through TGFb3 RNA levels were elevated during tumor progres-
sion. Papillomas expressed very low to undetectablethe benign tumor stage, could contribute to the in-
creased malignant conversion frequency. levels of TGFb3 RNA (data not shown), and there was
slightly elevated TGFb3 expression in some well-differ-
entiated carcinomas within the basal keratinocyte layerEndogenous TGFb3, TGFb1, or Both Are
Up-Regulated in Spindle (Figures 3G and 3H). TGFb3 expression was elevated
further in poorly differentiated squamous carcinomasCell Carcinomas
If TGFb1 drives the spindle cell conversion, extinction (Figures 3G and 3H) and persisted at very high levels in
6 out of the 7 spindle cell carcinomas examined (Figuresof transgene expression within the spindle tumors per
se (Figures 3E and 3F) suggests either that TGFb is 3I and 3J). The one exceptional spindle cell carcinoma
that expressed only low levels of TGFb3 had high levelsrequired for the conversion event, but not for mainte-
nance of the spindle phenotype, or that endogenous of endogenous TGFb1 expression (data not shown). En-
dogenous TGFb1 RNA and protein were detectable inTGFb(s) might fulfill the function of maintenance of the
spindle phenotype. To address this issue, we subjected some, but not all, spindle cell carcinomas (data not
shown). It is therefore apparent that there is a strong6 papillomas, 7 squamous carcinomas, and 7 spindle
Cell
536
increase in TGFb3 expression during multistage carci- et al., 1996). However, this keratin is only transiently
expressed in papillomas, as the protein is down-regu-nogenesis and that this growth factor could be involved
in maintenance of the spindle cell phenotype. lated as keratinocytes progress to malignancy. Cano
et al. (1996) reported two types of K13 expression, a
heterogeneous pattern, associated with a higher risk
TGFb1 Transgenic Papillomas Have a More of malignant conversion, and a homogeneous pattern,
Dysplastic Phenotype, with Altered K13 associated with a lower risk for malignant conversion.
and Integrin Expression In the present study, all tumors showed K13 expression,
TGFb1 might enhance malignant conversion frequency and homogeneous (Figures 5A and 5C) and heteroge-
in a number of ways, including evasion of host immune neous (Figures 5B and 5D) patterns were seen in both
surveillance, either locally or systemically (Torre-Amione control and transgenic tumors. However, in the M2 line,
et al., 1990; Arteaga et al., 1990), enhancement of angio- which showed the largest transgene effect in terms of
genesis (Roberts et al., 1986), or elevated apoptosis suppression of papilloma outgrowth and increased ma-
(Rotello et al., 1991; Lin and Chou, 1992; Bursch et al., lignant conversion, the K13 staining pattern was pre-
1992, 1993) leading to increased cell turnover and thus dominantly heterogeneous (5 of 6 tumors) compared
cell selection. Additionally, TGFb1 has been demon- with control tumors (5 of 11 with regions of heteroge-
strated to enhance tumor cell adhesion and survival neous K13 staining).
by altering expression of extracellular matrix and cell In addition to these observations of altered b4 integrin
adhesion molecules (Heino and Massague, 1989; Arrick and K13 expression patterns in the transgenic papillo-
et al., 1992; Chakrabarty, 1992; Chang et al., 1993; Wang mas, the use of immunohistochemical markers also re-
et al., 1995). To investigate the mechanism(s) whereby vealed an increased incidence of small dysplastic foci
recombinant TGFb1 enhanced the malignantconversion within the transgenic papillomas. Again, this was most
frequency and phenotype, we examined the transgenic apparent in the M2 line. These dysplastic foci were char-
papillomas for alterations in a number of histological acterized by elevated ubiquitous membranous a2 inte-
parameters. grin expression (Figure 5I), delocalized expression of a6
A number of studies have correlated changes in the and b4 integrin (Figure 5G), and heterogeneous or ab-
expression patterns of K13, E-cadherin, and a6b4 inte- sent staining for K13 (Figures 5B and 5D). Whereas only
grin with an altered risk for malignant conversion (Nischt 2 of 11 control papillomas contained these a2 integrin–
et al., 1988; Gomez et al., 1992; Tennenbaum et al., 1992, positive foci, 5 of 6 M2 papillomas had these dysplasias.
1993; Cano et al., 1996). Furthermore, TGFb1 has been Interestingly, the dysplastic foci were still E-cadherin
reported to up-regulate expression of a1, a2, and a5 positive (data not shown).
integrin, leading to enhanced tumor cell adhesion and Staining patterns for E-cadherin and a5 integrin were
survival (Heino and Massague, 1989; Arrick et al., 1992; identical in controls and transgenic papillomas, with the
Chakrabarty, 1992; Chang et al., 1993; Wang et al.,1995). anti-E-cadherin antibody showing ubiquitous mem-
We therefore examined expression of a2, a5, a6, and brane staining of suprabasal and occasionally basal ker-
b4 integrins, E-cadherin, and K13 in aged-matched pap- atinocytes (data not shown) and the anti-a5 integrin anti-
illomas of D, H, M2, M5, and control mice. The transgenic body showing predominant staining of the basal lamina
and control tumors were histologically very similar, but (data not shown). In the nondysplastic areas of trans-
the immunohistochemical studies revealed a number of genic and control tumors, a2 integrin was restricted to
subtle differences between the twotumor groups. These basal keratinocytes, particularly the basal lamina (Fig-
differences were most marked when comparing M2 with ure 4).
control tumors. The TGFb1 transgene clearly had an effect on the
It has been reported that in high risk tumors the do- cellular phenotype of the papillomas, characterized by
main of expression of a6b4 integrin is extended from altered integrin and K13 expression. In contrast, exami-
being predominantly basal to include suprabasal cells nation of the nuclear labeling indices for bromodeoxyuri-
(Gomez et al., 1992; Tennenbaum et al., 1993; Cano dine and estimation of the fraction of tumor cells under-
et al., 1996). In the current study, both transgenic and going apoptosis, as assessed using an in situ end
nontransgenic papillomas showed basal and suprabasal labeling approach (Ansari et al., 1993), revealed no clear
staining with the anti-a6 antibody (data not shown). differences between transgenics and controls (data not
However, throughout the whole tumor, there was a dif- shown), suggesting no remarkable effect of TGFb1 on
ference in both the staining intensity and cellular staining cellular proliferation or turnover within the papillomas.
pattern with the anti-b4 antibody (Figures 5E–5G). The
transgenic papillomas generally showed more intense
b4 staining than controls. Furthermore, whereas control Discussion
tumors (n 5 11) showed predominantly basal b4 staining
(Figure 5E), the transgenic tumors (n 5 17) had an ex- TGFb1 in Early Tumor Growth
A number of studies have addressed the role of TGFb1panded domain of b4 staining into the upper suprabasal
layers (Figure 5F). This was true for all the transgenic in epithelial tumor promotion (Akhurst et al., 1988; Fur-
stenberger et al., 1989; Pierce et al., 1995). Previ-lines examined.
K13 is not expressed in normal keratinocytes, but ously, intracutaneous injection of TGFb1, combined with
treatment by non-tumor-promoting hyperplasiogenicis switched on in papillomas (Nischt et al., 1988). Its
expression has been associated with a high risk for agents, suggested that TGFb1 is itself a tumor promoter
(Furstenberger et al., 1989). However, the present studymalignant progression (Tennenbaum et al., 1993; Cano
TGFb1 in Multistage Carcinogenesis
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Figure 5. Altered Expression of K13 and Integrins in Transgenic Papillomas
(A–D) Immunostaining with an anti-K13 antibody. (A) shows a control papilloma with a characteristic homogeneous K13 staining pattern in
suprabasal keratinocytes. (B) shows an H line papilloma with a region of homogeneous K13 staining in the upper left corner and an area of
dysplasia (surrounded by arrows) characterized by heterogeneous K13 staining. (C) shows a high power photomicrograph of the region of an
M2 papilloma staining homogeneously for K13. (D) shows a dysplastic region of the same M2 papilloma in (C) with heterogeneous K13 staining.
(E–G) Immunostaining with an anti–b4 integrin antibody. (E) shows a control papilloma, characterized by expression of b4 integrin restricted
to the basal lamina and basal keratinocytes. (F) shows a D line papilloma in which b4 integrin staining extends into the suprabasal keratinocyte
layers. (G) shows a region of dysplasia in a D line papilloma, where b4 integrin staining is extensive and there is loss of intense basal
keratinocyte staining.
(H and I) Immunostaining with an anti–a2 integrin antibody. (H) shows a control papilloma with a2 integrin staining characteristically restricted
to the basal lamina. (I) shows a region of dysplasia in an M2 papilloma where a2 integrin staining is extensive.
Abbreviations are as follows: adj, adjacent skin; b, basal layer; bl, basal lamina; k, keratin; sb, suprabasal keratinocytes; st, stroma. Scale
bar represents 250 mm in (A) and (B) and 62.5 mm in (C)–(I).
Cell
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definitively demonstrates the converse; that is, keratino- In contrast with the above reports, and consistent
with our present findings, a number of studies havecyte-derived TGFb1 inhibits benign tumor outgrowth.
This would complement the recent findings that TGFb1 demonstrated that TGFb1 gene expression constructs
transfected into tumor cell lines in vitro enhance theis a suppressor of mammary tumorigenesis in vivo in
mouse mammary tumor virus–TGFb1 transgenic mice malignant properties of the resultant tumors in vivo
(Welch et al., 1990; Torre-Amione et al., 1990; Arrick et(Pierce et al., 1995). In the skin model, it is most likely
that endogenous TGFb1, induced in normal epidermis al., 1992; Steiner and Barrack, 1992; Arteaga et al.,
1993a, 1993b; Chang et al., 1993). Indeed, in one study,in response to hyperplasia (Akhurst et al., 1988), is a
regulator of epidermal homeostasis (Cui et al., 1995). At TGFb1 overexpression led to an increased tumor mitotic
index in vivo, despite the fact that the tumor cells re-the early tumor promotion stages of carcinogenesis, the
predominant action of transgenic TGFb1 is on keratino- tained negative growth sensitivity to TGFb1 in vitro, sug-
gesting that the tumor-enhancing properties of TGFb1cyte growth inhibition (Haddow et al., 1991; Cui et al.,
1995; Fowlis et al., 1996), thus reducing the outgrowth predominated over negative growth regulation in vivo
(Chang et al., 1993).of benign tumors.
It isdifficult to reconcile all theseseemingly contradic-
tory observations because of the diversity of cell linesTGFb1 and Malignant Progression
The role of TGFb1 in malignant progression has been and experimental approaches taken. However, the re-
sults described in this report help to resolve these appar-controversial. Previous functional studies toaddress the
role of TGFb1 in skin carcinogenesis have been limited ent contradictions,since we have analyzed the functions
of TGFb at different steps of multistage carcinogenesisby the use of gene-transfected cultured tumor cells,
which were subsequently injected or grafted in vivo in vivo, in a single epithelial cell system. The well-docu-
mented negative regulatory effects of TGFb on growthto generate tumors, and different experimental ap-
proaches have led to divergent conclusions. The use of control of epithelial cells (Terzaghi-Howe, 1989; Haddow
et al., 1991; Manning et al., 1991; Missero et al., 1991)keratin promoter TGFb1 transgenic mice has allowed
us to address this problem directly, with the minimum would account for inhibition of benign tumor outgrowth
seen in the current study. Clearly, this type of mecha-of experimental intervention, by examination of the de
novo induction of skin tumors in vivo. Our data clearly nism could lead to the outgrowth of cells that have
acquired growth resistance through genetic alterationsshow that TGFb1 enhances malignant progression rate
and phenotype. in TGFb signaling, which in turn might lead to increased
proliferation and a higher probability of subsequent mu-A number of earlier studies showed that treatment
with TGFb1 antibodies or transfection of antisense tations that increase malignancy (Garrigue-Antar et al.,
1995; Markowitz et al., 1995). On the other hand, tumorTGFb1 gene expression constructs into malignant cells
in vitro enhanced the tumorigenicity of these cells after cells that evade negative growth regulation but retain
other aspects of TGFb cell signaling (Chen et al., 1993)injection into athymic mice in vivo (Arteaga et al., 1990;
Wu et al., 1992, 1993). Supporting this evidence, and could have greatermalignant capacity through their abil-
ity to undergo a TGFb-mediated switch to an invasivethus the proposal that TGFb1 predominantly protects
from malignant progression, is the observation that mesenchymal cell type (Miettinen et al., 1994; Caulin et
al., 1995; Portella et al., submitted).transfection with a TbRII-expressing gene construct di-
minished tumorigenicity (Sun et al., 1994). It has also
been shown that TGFb1null keratinocytes, transduced
TGFb1 and the Epithelial–Mesenchymal Transitionwith mutant v-rasHa in vitro and grafted onto athymic
The high incidence of malignant fibroblastoid spindlemice, produced tumors with an enhanced malignant
cell carcinomas in the transgenic mice is a particularlyconversion rate and malignant character compared
interesting observation. The ability of TGFb to inducewith wild-type keratinocytes (Glick et al., 1994). Further-
epithelial–mesenchymal transitions in embryonic cells inmore, immunohistochemical examination of endoge-
vitro has been reported utilizing the Xenopus mesodermnous TGFb1 expression levels in tumors in vivo has
induction assay (Kimelman and Kirschner, 1987) andalso supported the view that TGFb1 can protect from
an assay for transformation of chick endocardial cellsmalignant conversion. Elevation of TGFb1 expression
(Potts and Runyan, 1989). It is also interesting that TGFbhas been associated with mammary tumor regression
isoform expression during embryogenesis is often asso-(Jirtle et al., 1993), and we and others have shown that
ciated with sites of epithelial–mesenchymal transforma-lack of TGFb1 expression in TGFb1 growth-sensitive
tion, such as during cardiogenesis and palatogenesispapillomas is predictive of a high rate of conversion to
(Akhurst et al., 1990; Fitzpatrick et al., 1990; Pelton etsquamous carcinoma (Glick et al., 1993; Cui et al., 1994).
al., 1990; Millan et al., 1991). Furthermore, homozygousHowever, in all the above studies, TGFb1 was clearly
TGFb3 knockout mice are specifically defective instill acting as a potent suppressor of keratinocyte prolif-
palatal shelf fusion, which involves epithelial migrationeration (Arteaga et al., 1990; Wu et al., 1992, 1993; Glick
and an epithelial–mesenchymal transformation event,et al., 1993, 1994; Cui et al., 1994; Sun et al., 1994).
among other biological processes (Kaartinen et al.,In the current study, the effects of TGFb1 on cellular
1995; Proetzel et al., 1995). It is likely that TGFb syner-phenotype seem to have outweighed its effects as an
gizes with mitogenic growth factors in eliciting theseinhibitor of keratinocyte proliferation at the benign tumor
changes in epithelial plasticity (Anzano et al., 1982; Ki-stage, since there were no clear differences in cellular
melman and Kirschner, 1987; Dixon et al., 1991; Jouan-proliferation rates between transgenic and control
tumors. neau et al., 1991a). In the chemical carcinogenesis
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expression of native, latent mTGFb1. All mice were homozygous formodel, mutation of H-ras would serve this function,
the transgenes and had been bred through four generations ontosince epidermal growth factor (EGF) and fibroblast
an NIH/Olac inbred genetic background. Control mice were inbred
growth factor family members signal via the ras pathway NIH/Olac mice from the same breeding colony.
(Whitman and Melton, 1992; Umbhauer et al., 1995).
Furthermore mutant H-ras is known to mediate some Chemical Carcinogenesis
Tumors were induced in vivo by shaving the dorsal skins ofeffects via the EGF receptor and its ligands (Cheng et
z8-week-old female mice and, 2 days later, topically applying aal., 1993; Dlugosz et al., 1995).
single dose of 25 mg of DMBA in 200 ml of acetone. The mice wereUnderstanding the mechanism of the spindle cell
then treated twice a week for 20 weeks with TPA (200 ml of a 1024
transformation also has clinical relevance, since these M solution in acetone). The number of benign and malignant tumors
invasive tumor types are seen in human material (Berg- on each mouse was recorded every week for up to 44 weeks post-
DMBA. Benign tumor numbers did not increase after 26 weeks,mann et al., 1951; Battifora, 1976; Evans and Smith,
owing to discontinuation of TPA treatment. Mice were sacrificed if1980; Lenventon and Evans 1981), and reversible epithe-
moribund, if the tumor load was excessive, if any individual tumorlial–mesenchymal transformation has been proposed as
exceeded 10 mmin diameter, or at the termination of the experiment,
an important mechanism during tumor invasion and me- which was around 44 weeks post-DMBA. Each mouse was injected
tastasis (Valles et al., 1991; Jouanneau et al., 1991b; intraperitoneally with 50 mg of bromodeoxyuridine per gram of body
weight 1 hr before sacrifice. The tumors were snap-frozen in liquidMareel et al., 1993; G. Portella et al., unpublished data).
nitrogen and/or fixed overnight in freshly prepared 4% paraformal-TGFb1 can directly stimulate epithelial–mesenchymal
dehyde, followed by paraffin-embedding. Tumors were scored astransitions in cultured keratinocytes (Caulin et al., 1995;
carcinomas or papillomas by morphological appearance upon col-
G. Portella et al., unpublished data) and mammary epi- lection of the tumor. The tumors were further histologically graded
thelial cells (Miettinen et al., 1994) both in vitro and after after hematoxylin and eosin staining of paraffin sections.
injection into nude mice in vivo. This effect of TGFb1 in
In Situ Hybridizationenhancing the spindle cell conversion is certainly a di-
Paraffin sections (5 mm) were subjected to in situ hybridization usingrect effect on the keratinocyte, rather than being sec-
35S-labeled antisense or sense transgene-specific riboprobes (Cui et
ondary to stromal interactions or immunomodulatory al., 1995) or isoform-specific probes for TGFb1, TGFb2, and TGFb3
influences, since the epithelial–mesenchymal transition (Fitzpatrick et al., 1990). Autoradiographic exposures were for 8–12
can be seen after addition of TGFb1 to malignant kera- days. Photomicrography was performed on an Olympus BH2 micro-
scope using PANF film (Ilford).tinocytes in vitro (Caulin et al., 1995; G. Portella et al.,
unpublished data) and the spindle cell transition is
Antibodies and Immunohistochemical Stainingblocked in vivo by transfection of a dominant-negative Antibodies against TGFb1 were rabbit anti-LC (1-30-1), anti-CC
TbRII receptor gene construct into malignant keratino- (1-30-1), and anti-pre-266-278-1, all of which had been previously
cytes (G. Portella et al., unpublished data). The finding characterized with respect to specificity (Flanders et al., 1989;
Wakefield et al., 1990). These were applied to paraffin-embeddedthat recombinant TGFb1 can induce an epithelial–
tumor sections. Other antibodies included rat anti-E-cadherin (Ta-mesenchymal transition in vivocontributes to our under-
kara Biomedicals), rabbit anti-K13 (Nischt et al., 1988), rabbit anti–a2standing of the molecular mechanisms responsible for
integrin (Wu and Santoro, 1994), rabbit anti–a5 integrin (Hynes et
changes in cell plasticity essential to both embryogene- al., 1989), and rat anti–a6 and anti–b4 integrins (Falcioni et al., 1994),
sis and oncogenesis. which were used to stain cryosections of tumors.
Paraffin sections (5 mm) were deparaffinized, and endogenousAlthough transgenic TGFb1 expression was extin-
peroxidase was blocked for 20 min in 1.2% hydrogen peroxide inguished in the spindle cell tumors, endogenous TGFb3
methanol. Sections were preincubated at room temperature for 30and, to a lesser extent, TGFb1 were elevated in all the
min in 0.1% bovine serum albumin, 3% donkey serum, and 3%
spindle cell tumors examined. TGFb3 is characteristi- mouse serum and then overnight at 48C in the same mixture con-
cally expressed in fibroblast, as opposed to epithelial, taining antibody (z5 mg/ml). After washing in phosphate-buffered
saline, the primary antibody was detected using biotinylated donkeycell types (Millan et al., 1991), and its up-regulation in the
anti–rabbit or anti–rat IgG, followed by avidin–biotin complexspindle cells would be consistent with their fibroblastoid
(DAKO). Peroxidase was detected using diaminobenzidine as thephenotype. The enhanced expression of TGFb3 in spin-
chromogen. Cryosections were treated identically except these
dle cells might be a positive autoregulatory mechanism were prefixed either for 20 min in 4% paraformaldehyde (anti–a6
for maintenance of the spindle cell phenotype. and anti–b4 integrins, anti-K13 and anti-E-cadherin) or for 30–60 s
In conclusion, it is clear that TGFb1 has biphasic ef- in acetone (anti–a2 and a5 integrins).
fects during multistage carcinogenesis, acting as a
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